Nutrition and Inflammation in Patients With Head and Neck Cancer

Condition(s) studied

Investigational drug(s) / intervention(s)

Radiotherapy: All patients will undergo radiotherapy or surgery, or combined modality treatment

Study summary

An estimated 1500 people in Sweden will annually be diagnosed with head and neck cancer (HNC). Five year survival is approximately 69%. Long-term sequelae are common and in particular nutritional problems and fatigue. Radiotherapy (RT) is the cornerstone of treatment, either as single modality treatment or combined modality treatment. RT can induce immune responses at the site of tumor. It has been demonstrated that RT can lead to a strong systemic immune response . We have previously shown that an increase of conventional measures of systemic immune response to RT varied significantly across individuals. We predict that local immune response plays a major role in the antitumor effect. We also predict that a strong systemic immune response contributes to malnutrition and influence on survival. And malnutrition may lead to a worse response to RT.

The overall aim of this multicenter observational longitudinal study is to prospectively identify immunological and metabolic variables that affect the outcome of HNC patients. We will systematically investigate the local and systemic immune response induced by RT as well as explore alterations in metabolite composition induced by disease and treatment through global metabolite profiling. A platform for studies on immuno-metabolic changes in HNC patients has been established in the Uppsala-Orebro and Northern regions. Approximately 370 patients per year are eligible. Findings in this study can have implications on the development of personalized therapy in patients with HNC. The long-term benefit of the study will be the identification of measures for improved patient surveillance in order to improve the general and nutritional outcomes.

Eligibility

Primary outcome measure(s)

• Pro-inflammatory cytokines in serum — Change from baseline of pro-inflammatory cytokines in serum at 7 weeks
  IL-6
• Pro-inflammatory cytokines in serum — Change from baseline of pro-inflammatory cytokines at 3 months
  IL-6
• Pro-inflammatory cytokines in serum — Change from baseline of pro-inflammatory cytokines at 12 months
  IL-6

Trial sites (1)

More Uppsala University trials in Sweden

Other trials for the same condition